Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients

CA Wijbrandts, PH Remans… - … : Official Journal of …, 2008 - Wiley Online Library
Objective Infliximab treatment results in a decrease in synovial cellularity as early as 48
hours after initiation of therapy in patients with rheumatoid arthritis (RA). This study was …

Infliximab treatment shifts the balance between stimulatory and inhibitory Fcγ receptor type II isoforms on neutrophils in patients with rheumatoid arthritis

K Belostocki, L Pricop, PB Redecha… - … : Official Journal of …, 2008 - Wiley Online Library
Objective Human neutrophils express both activating and inhibitory Fcγ receptors (FcγR),
and their relative expression determines the inflammatory response to immune complexes …

The importance of reporting disease activity states in rheumatoid arthritis clinical trials

D Aletaha, J Funovits, JS Smolen - Arthritis & Rheumatism, 2008 - Wiley Online Library
Objective To compare the value of reporting treatment effects in rheumatoid arthritis (RA) as
relative change from baseline (eg, American College of Rheumatology [ACR] responder …

Etanercept

E Ducharme, JM Weinberg - Expert Opinion on Biological Therapy, 2008 - Taylor & Francis
Background: In some patients with psoriasis the inflammatory process fueling skin lesions
also afflicts their joints in a condition called psoriatic arthritis. TNF-α has been shown to play …

Anti-TNF antibodies: lessons from the past, roadmap for the future

DJ Shealy, S Visvanathan - Therapeutic Antibodies, 2008 - Springer
Tumor necrosis factor alpha (TNF) is an important cell-signaling component of the immune
system. Since its discovery over 20 years ago, much has been learned about its functions …

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-α antagonists

M Vera-Llonch, E Massarotti, F Wolfe… - The Journal of …, 2008 - jrheum.org
Objective To assess cost-effectiveness of abatacept in patients with rheumatoid arthritis (RA)
with inadequate response to tumor necrosis factor-α antagonists (anti-TNF). Methods We …

Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients

T Van Der Pouw Kraan, LGM Van Baarsen… - Genes & …, 2008 - nature.com
Rheumatoid arthritis (RA) is a heterogeneous disease with unknown etiology. Here we
aimed to distinguish RA subtypes based on peripheral blood (PB) gene expression profiles …

Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis

B Segal, NL Rhodus, K Patel - Oral Surgery, Oral Medicine, Oral Pathology …, 2008 - Elsevier
Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by inflammation
involving large and small joints. Systemic manifestations as well as involvement of paraoral …

Chromen-based TNF-α converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation

K Chun, SK Park, HM Kim, Y Choi, MH Kim… - Bioorganic & medicinal …, 2008 - Elsevier
A series of coumarin types MMP inhibitors were designed based on gelastatin
hydroxamates (1) and evaluated for TACE, cellular TNF-α, and NO inhibitory activities …

Advances in the diagnosis and immunotherapy for ocular inflammatory disease

S Yeh, LJ Faia, RB Nussenblatt - Seminars in immunopathology, 2008 - Springer
Significant advances in the diagnosis and therapy for uveitis have been made to improve the
quality of care for patients with ocular inflammatory diseases. While traditional ophthalmic …